Results 31 to 40 of about 503,937 (310)

PROMOTER POLYMORPHISMS OF GENES ENCODING TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 IN BREAST CANCER PATIENTS

Медицинская иммунология, 2017
Search for molecular genetic markers of risk and prognosis of breast cancer is an important prospective of modern research. Many molecular mechanisms are involved in pathogenesis of breast cancer and define a wide range of possible candidate genes.
A. N. Silkov, N. V. Cherdyntseva, V. N. Maximov, S. V. Sennikov   +3 more
doaj   +1 more source

Influence of Simvastatin and Interleukin 1 Receptor Antagonist on Expression of Aryl Hydrocarbon Receptors Under Experimental Acute Ileitis

Gastroenterologìa, 2015
Aryl hydrocarbon receptor (AhR) — transcription factor activated by a large number of environmental agents, and may play a role in the pathogenesis of inflammatory bowel diseases in humans and mouse models.
O.S. Zherebiatiev, O.M. Kamyshnyi
doaj   +1 more source

Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) [PDF]

, 2017
Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of con-firmed HF cases in the United States. However, there are no highly effective evidence-basedtreatments currently available for these patients.
Abbate, Antonio, Abouzaki, Nayef, Arena, Ross, Biondi-zoccai, Giuseppe, Buckley, Leo F., Canada, Justin M., Carbone, Salvatore, Dixon, Dave L., Oddi-erdle, Claudia, Trankle, Cory R., Van Tassell, Benjamin W.   +10 more
core   +1 more source

MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling

Journal of Hematology & Oncology, 2012
The discovery of miRNAs has revolutionized the way we examine the genome, RNA products, and the regulation of transcription and translation. Their ability to modulate protein expression through mRNA degradation and translation repression resulted in avid
Virtue Anthony, Wang Hong, Yang Xiao-feng   +2 more
doaj   +1 more source

Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein [PDF]

Proceedings of the National Academy of Sciences, 1997
The proinflammatory cytokine interleukin 1 (IL-1) activates the transcription of many genes encoding acute phase and proinflammatory proteins, a function mediated primarily by the transcription factor NF-κB. An early IL-1 signaling event is the recruitment of the Ser/Thr kinase IRAK to the type I IL-1 receptor (IL-1RI). Here we describe the function of
J, Huang, X, Gao, S, Li, Z, Cao
openaire   +2 more sources

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul, Jatuporn Sujjitjoon, Pa‐thai Yenchitsomanus, Kridtin Jarutatsanangkoon, Ng Wei Loon, Kleebsabai Sanpakit, Jassada Buaboonnam, Chayamon Takpradit, Pornpimon Yuti, Nunghathai Sawasdee, Piriya Luangwattananun, Siripakorn Sangkitporn, Arnan Limmahachai, La‐ongsri Atchaneeyasakul   +13 more
wiley   +1 more source

Ligand induced cleavage and nuclear localization of the rice XA21 immune receptor [PDF]

, 2012
The rice XA21 receptor confers immunity to the Gram-negative bacterial pathogen, _Xanthomonas oryzae_ pv. _oryzae_ (_Xoo_) upon recognition of the conserved microbial signature AxY^S^22.
Chang-Jin Park, Pamela C. Ronald
core   +1 more source

Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within ...
Marie C. Heider, Amelie Alfert, Marc Hotfilder, Birgit Burkardt, Marcel te Vrugt   +4 more
wiley   +1 more source

The interleukin‐1 receptor antagonist influences interleukin‐1 effects in rat and mouse [PDF]

Mediators of Inflammation, 1992
In this work we have focused on the ability of interleukin‐1 to induce an acute phase protein response and a degranulation of polymorphonuclear leukocytes in vivo. The capacity of the interleukin‐1 receptor antagonist to influence these events was also investigated.
P. Bjrök, K. Ohlsson
openaire   +3 more sources

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source